Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

AstraZeneca unveils second brand play in India

This article was originally published in Scrip

Executive Summary

AstraZeneca appears to be the latest to join a clutch of foreign firms deploying the second-brand approach to penetrate the Indian market more effectively.

You may also be interested in...



Eisai-Mylan Tango for Second Halaven Brand In India But Eyes On Pricing, Generics

Eisai has struck a deal with Mylan for a second brand of Halaven in India, joining a growing list of foreign firms deploying this approach to expand access to novel therapies in the country amid emerging competition.

AZ's Brilinta Patents 'Vulnerable' To Challenge In India

An Indian court has lifted restraining orders against Micro Labs, Dr Reddy’s and Natco and held that they have made a “strong credible challenge” to the validity of AstraZeneca’s patents for Brilinta in the country. The UK firm has appealed the order.

AstraZeneca Seeks To Ward Off Brilinta Patent Infringer In India

An Indian court has blocked an alleged infringer of AstraZeneca's patent pertaining to Brilinta (ticagrelor), but the case, some experts claim, also brings to the fore certain controversial tactics at play in the legal arena as large firms pursue litigation to safeguard their intellectual property.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

SC028884

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel